| Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology WJ Gradishar, MS Moran, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 20 (6), 691-722, 2022 | 571 | 2022 |
| TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ... Journal of Clinical Oncology 37 (13), 1081-1089, 2019 | 327 | 2019 |
| A deep learning method for classifying mammographic breast density categories AA Mohamed, WA Berg, H Peng, Y Luo, RC Jankowitz, S Wu Medical physics 45 (1), 314-321, 2018 | 284 | 2018 |
| NCCN guidelines® insights: Breast cancer, version 4.2021: Featured updates to the NCCN guidelines WJ Gradishar, MS Moran, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 19 (5), 484-493, 2021 | 265 | 2021 |
| Breast cancer index identifies early-stage estrogen receptor–positive breast cancer patients at risk for early-and late-distant recurrence Y Zhang, CA Schnabel, BE Schroeder, PL Jerevall, RC Jankowitz, ... Clinical Cancer Research 19 (15), 4196-4205, 2013 | 256 | 2013 |
| Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis ME Klein, DJ Dabbs, Y Shuai, AM Brufsky, R Jankowitz, SL Puhalla, ... Modern Pathology 26 (5), 658-664, 2013 | 208 | 2013 |
| Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores J Lecarpentier, V Silvestri, KB Kuchenbaecker, D Barrowdale, J Dennis, ... Journal of Clinical Oncology 35 (20), 2240-2250, 2017 | 190 | 2017 |
| Epigenetics in breast cancer: what's new? Y Huang, S Nayak, R Jankowitz, NE Davidson, S Oesterreich Breast Cancer Research 13, 1-11, 2011 | 180 | 2011 |
| Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes L Fachal, H Aschard, J Beesley, DR Barnes, J Allen, S Kar, KA Pooley, ... Nature genetics 52 (1), 56-73, 2020 | 158 | 2020 |
| Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer CM Bender, AL Gentry, AM Brufsky, FE Casillo, SM Cohen, MM Dailey, ... Oncology nursing forum 41 (3), 274, 2014 | 151 | 2014 |
| Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: a phase II National Cancer Institute/Stand Up to Cancer Study RM Connolly, H Li, RC Jankowitz, Z Zhang, MA Rudek, SC Jeter, ... Clinical cancer research 23 (11), 2691-2701, 2017 | 143 | 2017 |
| NCCN Guidelines® Insights: breast cancer, version 4.2023: featured updates to the NCCN guidelines WJ Gradishar, MS Moran, J Abraham, V Abramson, R Aft, D Agnese, ... Journal of the National Comprehensive Cancer Network 21 (6), 594-608, 2023 | 137 | 2023 |
| Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer MA Ferreira, ER Gamazon, F Al-Ejeh, K Aittomäki, IL Andrulis, ... Nature communications 10 (1), 1741, 2019 | 131 | 2019 |
| Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ... Journal of Clinical Oncology 39 (21), 2375-2385, 2021 | 114 | 2021 |
| Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast A Mathew, PS Rajagopal, V Villgran, GS Sandhu, RC Jankowitz, M Jacob, ... Geburtshilfe und Frauenheilkunde 77 (06), 660-666, 2017 | 113 | 2017 |
| Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma SA Jacobs, SH Swerdlow, J Kant, KA Foon, R Jankowitz, SR Land, ... Clinical Cancer Research 14 (21), 7088-7094, 2008 | 113 | 2008 |
| Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy M Han, A Salamat, L Zhu, H Zhang, BZ Clark, DJ Dabbs, GJ Carter, ... Modern Pathology 32 (6), 807-816, 2019 | 73 | 2019 |
| Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10 J Abraham, AJ Montero, RC Jankowitz, MA Salkeni, JH Beumer, ... Journal of Clinical Oncology 37 (29), 2601-2609, 2019 | 71 | 2019 |
| Low Estrogen Receptor (ER)–positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease? A Landmann, DJ Farrugia, L Zhu, EJ Diego, RR Johnson, A Soran, ... American journal of clinical pathology 150 (1), 34-42, 2018 | 71 | 2018 |
| Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research … RC Jankowitz, J Abraham, AR Tan, SA Limentani, MB Tierno, ... Cancer chemotherapy and pharmacology 72, 1205-1212, 2013 | 71 | 2013 |
